Thursday, 15 October 2026European Markets

TIPIAK And HEINEKEN Have A High Dividend Yield And Return On Equity In The Consumer Defensive Sector.

Loading stream...

(vianews) - tipiak (tipi.pa) is among this list of stock assets with the highest dividend rate and return on equity on the consumer defensive sector.

financial asset price forward dividend yield return on equity
tipiak (tipi.pa) €85.50 2.48% 2.88%
heineken (heia.as) €91.18 2.1% 12.7%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. tipiak (tipi.pa)

2.48% forward dividend yield and 2.88% return on equity

tipiak société anonyme, a food company, manufactures prepared food products, frozen ready-meals, pastry products, groceries, and crusty bread products. the company offers groceries, such as breadcrumbs, cereals, couscous, croutons, japanese pearls, potato starch, quinoa, and tapioca; frozen products, including savory products, appetizers, and side dishes with grains; and frozen sweet products comprising macarons, mini eclairs, and petits fours. it sells its products in france, england, and the united states. the company was founded in 1830 and is based in saint-aignan-grandlieu, france.

earnings per share

as for profitability, tipiak has a trailing twelve months eps of €1.85.

pe ratio

tipiak has a trailing twelve months price to earnings ratio of 46.22. meaning, the purchaser of the share is investing €46.22 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 2.88%.

revenue growth

year-on-year quarterly revenue growth declined by 0.3%, now sitting on 239.09m for the twelve trailing months.

volume

today's last reported volume for tipiak is 45 which is 83.92% below its average volume of 280.

yearly top and bottom value

tipiak's stock is valued at €85.50 at 11:30 est, way higher than its 52-week high of €70.00.

more news about tipiak.

2. heineken (heia.as)

2.1% forward dividend yield and 12.7% return on equity

heineken n.v. brews and sells beer and cider in europe, americas, africa, the middle east, eastern europe, and the asia pacific. the company also provides soft drinks and water. it offers its beers under the heineken, amstel, sol, tiger, birra moretti, pure piraña, desperados, edelweiss, and lagunitas brands; and cider under the strongbow apple ciders, orchard thieves, cidrerie stassen, bulmers, and old mout brands, as well as under regional and local brands. the company offers its products to retailers, wholesalers, cafes, bars, pubs, hotels, and restaurants. heineken n.v. was founded in 1864 and is headquartered in amsterdam, the netherlands. heineken n.v. operates as a subsidiary of heineken holding n.v.

earnings per share

as for profitability, heineken has a trailing twelve months eps of €4.49.

pe ratio

heineken has a trailing twelve months price to earnings ratio of 20.31. meaning, the purchaser of the share is investing €20.31 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.7%.

volume

today's last reported volume for heineken is 129703 which is 73.52% below its average volume of 489852.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, heineken's stock is considered to be overbought (>=80).

volatility

heineken's last week, last month's, and last quarter's current intraday variation average was a negative 0.10%, a negative 0.06%, and a positive 0.74%.

heineken's highest amplitude of average volatility was 0.30% (last week), 0.56% (last month), and 0.74% (last quarter).

more news about heineken.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com